FindingCorroborated
STK11 loss sensitizes NSCLC lines to mTOR inhibition.
Scope: 14 lung adenocarcinoma lines, DepMap CRISPR + drug-response.
RefutationReportReproduceLiterature
01Specification✓ passed · 3/3
Claim is well-posed; variables and effect direction are unambiguous.
02Data robustness✓ passed · 4/4
Holds under resampling, batch correction, and outlier removal.
03Literature✓ passed · 2/2
Consistent with two independent reports; no direct contradiction found.
04Replication✓ passed · 2/2
Reproduces on a held-out cohort and an orthogonal assay.
Corroborated · survived 11 of 11 testsNo test designed to break this claim succeeded. Frozen with its data and code.